SPONSOR
French Innovative Leukemia Organisation
Total Trials
2
Recruiting
2
Phases
Phase 2
NCT06022003 Phase 2
Recruiting
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
AML, Adult
NCT06263387
Recruiting
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
AML, Adult